C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS

    公开(公告)号:EP3730146A1

    公开(公告)日:2020-10-28

    申请号:EP20167187.2

    申请日:2014-03-28

    IPC分类号: A61K35/66 A61P35/00

    摘要: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1 x 10 3 -1 x 10 7 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a human, methods for ablating a solid tumor present in a human, a method for microscopically precise excision of tumor cells in a human, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a human, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a human are also provided.

    A METHOD FOR GENERATING HYPERMUTABLE ORGANISMS
    7.
    发明公开
    A METHOD FOR GENERATING HYPERMUTABLE ORGANISMS 有权
    方法ZUR HERSTELLUNG HYPERMUTAGENISIERTER ORGANISMEN

    公开(公告)号:EP1430123A2

    公开(公告)日:2004-06-23

    申请号:EP01935403.4

    申请日:2001-05-14

    摘要: PROBLEM TO BE SOLVED: To provide a method for rendering cells hypermutable, and hypermutable cell lines altered genetically and phenotypically.SOLUTION: The invention relates to use of dominant negative alleles of human mismatch repair genes to generate hypermutable cells and organisms; the use of introducing genes into cells and transgenic animals by which new cell lines and animal varieties with new and useful properties can be prepared more efficiently than by relying on the natural rate of mutation; and use of mutagens for enhancing a rate of further augmented mutation.

    摘要翻译: 要解决的问题:提供一种使细胞变性可变的方法,以及基因和表型改变的超可变细胞系。解决方案:本发明涉及人错配修复基因的显性阴性等位基因用于产生超可变细胞和生物体; 将基因导入细胞和转基因动物中,通过其可以比通过依赖于自然的突变率更有效地制备具有新的和有用的性质的新的细胞系和动物品种; 并使用诱变剂提高进一步增强突变率。

    CDK4 IS A TARGET OF c-MYC
    8.
    发明公开
    CDK4 IS A TARGET OF c-MYC 审中-公开
    CDK4是C-MYC的目标

    公开(公告)号:EP1320612A2

    公开(公告)日:2003-06-25

    申请号:EP01910499.1

    申请日:2001-02-09

    IPC分类号: C12N15/54 C12N9/12 C12Q1/68

    CPC分类号: C12N9/1205

    摘要: The prototypic oncogene c-MYC encodes a transcription factor, which can drive proliferation by promoting cell cycle re-entry. However, the mechanisms through which c-MYC achieves these effects have been unclear. Using serial analysis of gene expression (SAGE), we have identified the cyclin dependent kinase 4 (CDK4) gene as a transcriptional target of c-MYC. c-MYC induced a rapid increase in CDK4 mRNA levels through four highly conserved c-Myc binding sites (MBS) within the CDK4 promoter. Cell cycle progression is delayed in c-MYC-deficient RAT1 cells, and this delay was associated with a defect in CDK4 induction. Ectopic expression of CDK4 in these cells partially alleviated the growth defect. Thus CDK4 provides a direct link between the oncogenic effects of c-MYC and cell cycle regulation.